The CMT64 syngeneic model allows proof of concept studies to evaluate the efficacy, mechanism of action, and the pharmacodynamics of such TGF-β inhibitors for the treatment of lung adenocarcinoma. Here, TGFB1 is linked to lung adenocarcinoma.